Text version
Greetings! This is David Rosenberg from the Psychopharmacology Institute. In this CAP—or Child and Adolescent Psychiatry—Smart Take, we will explore an under-researched yet vital area in child and adolescent psychiatry—specifically, the initiation of long-acting injectable aripiprazole lauroxil in adolescents hospitalized due to diverse conditions, such as schizophrenia, major depression with psychotic features, and unspecified mood disorders. The use of long-acting injectable antipsychotics in youth is not well-established; indeed, evidence is scarce. However, this approach is often necessary and utilized in hospitalized youth who display aggression, cannot tolerate traditional antipsychotic oral medication, or are noncompliant or nonadherent to medication regimens.
This study presents a crucial retrospective chart review focused on initiating aripiprazole lauroxil—a long-acting injectable antipsychotic—in youth. The data covers an adolescent psychiatric inpatient unit from March 2021–March 2023. Within this analysis, researchers identified 12 adolescents who received aripiprazole lauroxil within 2 years; the mean age was 16. Seven of the
Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
